PhotonPharma raised $2.5M in Seed funding to support the Phase I clinical trial of Innocell™, an innovative therapy for advanced ovarian cancer.
PhotonPharma raised $2.5M in Seed funding to support the Phase I clinical trial of Innocell™, an innovative therapy for advanced ovarian cancer.
08/22/24, 11:08 PM
Location
fort collinsMoney raised
$2.5 million
Industry
biotechnology
Round Type
seed
PhotonPharma, a biopharmaceutical company based in Fort Collins, CO, secured $2.5M in Seed funding. The funds will be used to advance the Phase I clinical trial of Innocell™, aimed at treating advanced ovarian cancer.
Company Info
Location
3185 rampart road
fort collins, colorado, united states
Additional Info
PhotonPharma is dedicated to developing innovative autologous cancer therapies that leverage the body's immune system to fight disease. With a focus on personalized medicine, the company's lead product, Innocell™, aims to provide a safe and effective therapy for a wide range of solid organ tumors. In February 2024, PhotonPharma received FDA clearance for the company's first Phase 1 study in the US: a first-in-human clinical study for stage III/IV ovarian cancer treatment with the investigational autologous vaccine therapy, Innocell™. The company has partnered with the City of Hope in Los Angeles to conduct the study. The Phase 1 clinical trial for Innocell™ will evaluate its safety, tolerability, and immune response indicators in patients with Stage III/IV ovarian cancer. PhotonPharma anticipates initiating patient enrollment in the near future.